Jiaowu Cao
YOU?
Author Swipe
View article: EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma Open
View article: PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma
PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma Open
Relapsed or refractory diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patients still faced with poor survival, representing an unmet clinical need. In-depth research into the disease's pathogenesis and the development…
View article: Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy Open
View article: Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma
Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma Open
CD47 expressed on cancer cells enables macrophage immune evasion. Blocking CD47 using anti‐CD47 monoclonal antibodies (mAbs) is a promising strategy. The anti‐CD47 mAb TJC4 has anti‐tumor activity but lacks hematological toxicity. Venetocl…
View article: Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patients
Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patients Open
Background: The clinical implication of circulating tumor DNA (ctDNA) as a prognostic or predictive biomarker in DLBCL patients receiving standard immunochemotherapy is uncertain. Methods: Here, using targeted next-generation sequencing, w…
View article: Additional file 1 of Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Additional file 1 of Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy Open
Additional file 1: Table S1. Gene list of Onco-LymScan panel. Table S2. Overview of patient characteristics. Table S3. Demographic of patient characteristics. Table S4. Sequencing quality data of tumor gDNA samples. Table S5. Sequencing qu…
View article: Ibrutinib Combined With Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma
Ibrutinib Combined With Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma Open